vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update
November 10, 2022 17:25 ET
|
vTv Therapeutics Inc.
Company on-track to initiate Phase 3 clinical trials of TTP399 in the first quarter of 2023 Industry veteran Paul Sekhri joins the Company as President, Chief Executive Officer, and member of the...
vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update
August 15, 2022 18:43 ET
|
vTv Therapeutics Inc.
Paul Sekhri appointed as President, Chief Executive Officer and Board member. Entered into agreements with CinRx Pharma and a subsidiary to purchase $10 million in stock and to leverage CinRx’s...
vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer
July 27, 2022 07:00 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for...
vTv Therapeutics Announces Investment by CinRx Pharma
July 25, 2022 07:00 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC (“CinPax”), a...
vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
June 04, 2022 11:00 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., June 04, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for...
vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare
June 01, 2022 06:54 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $25 million investment by G42 Investments AI Holding RSC...
vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update
May 12, 2022 07:45 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2022, and provided an update on the...
vTv Therapeutics Shares Updated Corporate Presentation
January 13, 2022 08:30 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Jan. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company committed to improving the quality of life for people with...
vTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations
December 06, 2021 17:19 ET
|
vTv Therapeutics Inc.
-Workforce reduction of 65% -Prioritization of lead program TTP399, a potentially transformative treatment for the reduction of hypoglycemic episodes in type 1 diabetes patients HIGH POINT, N.C.,...
vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update
November 09, 2021 08:30 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2021, and provided an update on the...